John E. Bisi

TL;DR: Nuclear microinjection of cells constitutively expressing SV40 large T antigen with either a 15-mer or 20-mer PNA targeted to the T Ag messenger RNA suppressed T Ag expression, and Binding of PNAs to RNA resulted in site-specific termination of both reverse transcription and in vitro translation.

TL;DR: It is shown that short-term exposure to small-molecule inhibitors of cyclin-dependent kinases 4 and 6 significantly enhances T- cell activation, contributing to antitumor effects in vivo, due in part to the derepression of NFAT family proteins and their target genes, critical regulators of T-cell function.

TL;DR: The present data support a possible role for CDK4/6 inhibitors in a majority of patients with advanced cancer and suggest statistically significant protection of platelets in tumor-bearing mice.

TL;DR: It is concluded that PNAs could be effective antisense agents with additional chemical modification that will lead to more rapid association with their RNA target.

TL;DR: It is shown that ErbB2 regulates survivin protein expression in Erb B2-overexpressing breast cancer cells, shedding new light on the mechanism by which ErbK2 overexpression protects against apoptotic stimuli in breast cancer and identifies therapeutic interventions to improve clinical outcomes in these aggressive tumors.